Commitments and Contingencies Leases Refer to Note 7, Leases , for a discussion of the commitments associated with the Companys lease agreements. Northwestern University License Agreements On December 12, 2011, (1) AuraSense, LLC, the Companys former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLCs 2009 license agreement with Northwestern University (NU) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the Assigned Field); (2) in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3) in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Companys sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensees sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company. In August 2015, the Company entered into a restated license agreement with NU (the Restated License Agreement). In February 2016, the Company obtained exclusive license as to NUs rights in certain SNA technology it jointly owns with NU (the Co-owned Technology License). The Companys license to NUs rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the Wound Healing License). The Companys rights and obligations in the Co-owned Technology License and the Wound Healing License agreements are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as the Northwestern University License Agreements). As of December 31, 2019, all pending patent applications under the Wound Healing License have been abandoned. As of September 30, 2020, the Company has paid to NU an aggregate of $8,279 in consideration of each of the obligations described above.